On March 8, 2022 Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) ("Checkmate"), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, reported that it will present biomarker data at the 2022 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place in New Orleans, Louisiana from April 8-13, 2022 (Press release, Checkmate Pharmaceuticals, MAR 8, 2022, View Source [SID1234609799]). An e-poster will be made available online starting Friday, April 8 at 1:00pm ET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentation Details:
Title: Novel transcriptional signatures associated with antitumor activity in vidutolimod (vidu)-treated patients (pts) with anti-PD-1-refractory melanoma and non-small cell lung cancer (NSCLC)
Presenting Author: Art Krieg, M.D.
Abstract #: LB107
Session Title: Late-Breaking Research: Clinical Research 2
Session Date and Time: Tuesday, April 12, 2022, 9:00am – 12:30pm CT
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 17, Poster Board #1